<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442948</url>
  </required_header>
  <id_info>
    <org_study_id>CD16PHAMOS</org_study_id>
    <nct_id>NCT01442948</nct_id>
  </id_info>
  <brief_title>CD16+ Monocytes in Coronary Heart Disease (CHD)</brief_title>
  <acronym>PHAMOS</acronym>
  <official_title>CD16+ Monocytes in Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocytes may be separated into phenotypically and functionally distinct cell types by the
      presence or absence of the lipopolysaccharide receptor CD14 and the Fcγ-receptor CD16. The
      investigators hypothesize that the total numbers of CD16+ monocytes are significantly related
      to cardiovascular outcome in patients with angiographically proven coronary heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute numbers of CD16+ monocytes stratified by tertiles related to the incidence of the combined endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of the combined endpoint (non-fatal myocardial infarction, cardiovascular death, stroke) during a follow-up of 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute numbers of CD16+ monocytes stratified by tertiles related to the incidence of each part of the combined endpoint + total death</measure>
    <time_frame>12 months</time_frame>
    <description>non-fatal myocardial infarction
cardiovascular death
stroke
total death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis for absolute numbers of CD16+ monocytes stratified by tertiles in relation to the combined endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Subgroups of patients:
Patients with stable Angina Patients with acute coronary syndrome</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Acute coronary syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable Angina</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with angiographically proven coronary heart disease, admitted to the Department of
        Medicine or Department of Cardiothoracic Surgery of the Martin Luther-University
        Halle-Wittenberg
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  angiographically proven coronary heart disease

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  life expectancy &lt; 12 months

          -  inability to participate in the trial (to give written informed consent)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Clinic of the Martin Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Please Select</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>September 28, 2011</last_update_submitted>
  <last_update_submitted_qc>September 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Axel Schlitt</investigator_full_name>
    <investigator_title>Senior Physician</investigator_title>
  </responsible_party>
  <keyword>-CD16+ monocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

